poisar

Stocks · News reference

RBC Capital Maintains Outperform on DexCom, Raises Price Target to $90

Benzinga Newsdesk

RBC Capital analyst Kendall Au maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $85 to $90.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

DXCM
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks.Com

    Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today

    A $1,000 investment in DexCom (DXCM) made 10 years ago in August 2016 would be worth $3,981.59 as of August 31, 2026, representing a 298.16% gain. This significantly outperformed the S&P 500's 255.54% gain over the same period. DexCom, a medical device company specializing in continuous glucose monitoring systems, reported 2025 revenues of $4.66 billion (up 16% YoY) and adjusted EPS of $2.09 (up 27.4% YoY). Analysts remain optimistic about future growth despite competitive market pressures.

    DXCM